Andrew Reardon, CLO & Secretary at LIGAND PHARMACEUTICALS INC (LGND), sold 5,000 shares at $284.14 ($1.4M) on 2026-08-03, disclosed to the SEC on 2026-08-04.
Scheduled sale ($1.4M) by CLO & Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $284.14 | 105 | $30K | 2.1% |
| 2 | $284.55 | 33 | $9K | 0.6% |
| 3 | $285.74 | 157 | $45K | 3.1% |
| 4 | $286.80 | 1,032 | $296K | 20.5% |
| 5 | $287.77 | 1,214 | $349K | 24.2% |
| 6 | $288.75 | 356 |
| $103K |
| 7.1% |
| 7 | $289.80 | 503 | $146K | 10.1% |
| 8 | $290.60 | 200 | $58K | 4.0% |
| 9 | $291.71 | 991 | $289K | 20.0% |
| 10 | $292.82 | 409 | $120K | 8.3% |
| Total | $288.99 avg | 5,000 | $1.4M | 100% |
| Filing → |
| LGND | SELL | 2026-07-06 | $1.6M | — | Filing → |
| LGND | SELL | 2026-06-02 | $1.1M | — | Filing → |
| LGND | SELL | 2026-05-04 | $1.2M | — | Filing → |